Pharvaris N.V.
NASDAQ:PHVS · NASDAQ Global Select
-$0.64 today
Vol 0.18M · Avg 0.31M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-64.8%
avg -42.1%
ROIC
-62.4%
avg -43.4%
ROA
-58.3%
avg -38.6%
Analysis
ROA is currently the strongest return metric at -58.3% versus its period average of -38.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Berndt Axel Edvard Modig | Co-Founder, Chief Executive Officer & Executive Director | $1.59M | — | 67 | $135,309.00 | 0.19% |
Maryann Cimino | Director of Corporate Relations | — | — | — | — | — |
Wim Souverijns | Chief Commercial Officer | — | — | 55 | $45,111.00 | 0.06% |
Anna Nijdam | Head of Strategic Finance & Principal Accounting Officer | — | — | 45 | $46,275.00 | 0.07% |
Anne Lesage | Chief Early Development Officer | — | — | 65 | $82,000.00 | 0.12% |
Peng Lu | Chief Medical Officer | — | — | 48 | $65,631.00 | 0.09% |
Annick Deschoolmeester | Chief Human Resources Officer | — | — | 53 | $0.00 | <0.01% |
David W. Nassif | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | — | — | 72 | $0.00 | <0.01% |
Stefan Abele | Chief Technology Operations Officer | — | — | 56 | $35,194.00 | 0.05% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
36
$7.11M
Net Sentiment
$7.11M
Net selling
Most Active
Lesage Anne
9 transactions
1–10 of 36
Analysis
Insiders reported 0 buys worth $0.00 and 36 sells worth $7.11M over the last 12 months. That adds up to net selling of $7.11M. Lesage Anne was the most active insider with 9 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.33B
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.52B
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$1.90B
Immunome, Inc.
NASDAQ:IMNM
$1.74B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.71B
Zymeworks Inc.
NASDAQ:ZYME
$1.67B
Ardelyx, Inc.
NASDAQ:ARDX
$1.45B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.39B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$882.50M
Upstream Bio, Inc.
NASDAQ:UPB
$338.45M
Who manages PHVS?
Pharvaris N.V. (PHVS) lists 9 active executives. The top listed executive is Maryann Cimino, Director of Corporate Relations.
Are PHVS insiders buying or selling?
Recent insider activity shows net selling of $7.22M.
Explore More
Continue the stock analysis
Jump to another research area for this company.